The hero of the global First-in Class is Hanmi
Pharmaceutical.
Hanmi Pharmaceutical is developing in the areas of anti-cancer,
obesity, diabetes, and rare diseases.
Last updated 2022-07-02
Research Area |
Project | Indication | Preclinical | Clinical | Licensing | |||
---|---|---|---|---|---|---|---|---|
Phase 1 | Phase 2 | Phase 3 | Registration | |||||
BIO |
Rolontis®(eflapegrastim) Every three weeks administration
Spectrum |
Chemotherapy-induced neutropenia |
complete |
complete |
complete |
complete |
complete |
Spectrum |
efpeglenatideLAPSExd4 Analog Once weekly~monthly administration
|
Diabetes |
complete |
complete |
complete |
complete |
uncompleted |
none |
|
efinopegdutide(LAPSGLP/GCG) Once weekly administration
none |
NASH |
complete |
complete |
On going |
uncompleted |
uncompleted |
MSD |
|
HM15211(LAPSTriple Agonist) Once weekly administration (Glucagon/GIP/GLP-1)
none |
NASH |
complete |
complete |
On going |
uncompleted |
uncompleted |
none |
|
HM15136(LAPSGlucagon Analog) Once weekly administration
none |
Congenital hyperinsulinism |
complete |
complete |
On going |
uncompleted |
uncompleted |
none |
|
HM15912(LAPSGLP-2 Analog) Once monthly administration
none |
Short bowel syndrome |
complete |
complete |
On going |
uncompleted |
uncompleted |
none |
|
efpegsomatropin(LAPShGH) Once weekly administration
none |
Growth hormone deficiency |
complete |
complete |
complete |
uncompleted |
uncompleted |
none |
|
Rolontis®(eflapegrastim) Every three weeks administration Same-day administration
Spectrum |
Chemotherapy-induced neutropenia |
complete |
On going |
uncompleted |
uncompleted |
uncompleted |
Spectrum |
|
HM12470(LAPSInsulin Analog) Once weekly administration
none |
Diabetes |
complete |
complete |
uncompleted |
uncompleted |
uncompleted |
none |
|
HM15211(LAPSTriple Agonist) Once weekly administration (Glucagon/GIP/GLP-1)
none |
Idiopathic pulmonary fibrosis |
complete |
uncompleted |
uncompleted |
uncompleted |
uncompleted |
none |
|
LAPSGlucagon Combo(HM15136 + efpeglenatide) Once weekly administration
none |
Obesity |
complete |
uncompleted |
uncompleted |
uncompleted |
uncompleted |
none |
|
LAPSInsulin Combo(HM12470 + efpeglenatide) Once weekly administration
|
Diabetes |
complete |
uncompleted |
uncompleted |
uncompleted |
uncompleted |
none |
|
HM15450(Long-acting ASB) Once monthly administration
none |
Mucopolysaccharidosis |
complete |
uncompleted |
uncompleted |
uncompleted |
uncompleted |
none |
|
HM15421(Long-acting GLA)
none |
Fabry disease |
complete |
uncompleted |
uncompleted |
uncompleted |
uncompleted |
none |
|
HM16390(LAPSIL-2 Analog)
none |
Solid tumors |
complete |
uncompleted |
uncompleted |
uncompleted |
uncompleted |
none |
Research area |
Project | Indication | Preclinical | Clinical | Licensing | |||
---|---|---|---|---|---|---|---|---|
Phase 1 | Phase 2 | Phase 3 | Registration | |||||
NCE |
poziotinib(pan-HER) pan-HER inhibitor for multi-targeted anti-cancer drug second-line therapy
Spectrum |
HER2 exon 20–mutated NSCLC |
complete |
complete |
complete |
complete |
complete |
Spectrum |
Oraxol®(paclitaxel + encequidar) Oral paclitaxel encequidar: Oral absorption enhancer
Athenex |
Solid tumors (breast cancer) |
complete |
complete |
complete |
complete |
complete |
Athenex |
|
poziotinib(pan-HER) pan-HER inhibitor for multi-targeted anti-cancer drug first-line therapy
Spectrum |
NSCLC |
complete |
complete |
on going |
uncompleted |
none |
Spectrum |
|
Luminate®(ALG-1001) Integrin modulator
|
Dry age-related mascular degeneration |
complete |
complete |
on going |
uncompleted |
none |
![]() ![]() |
|
poseltinib(BTK) Bruton's tyrosine kinase inhibitor
|
Autoimmune disease |
complete |
complete |
on going |
uncompleted |
none |
none |
|
FLX475(CCR4) Selective oral CCR4 antagonists
|
Solid tumors |
complete |
complete |
on going |
uncompleted |
none |
![]() ![]() |
|
belvarafenib(pan-RAF) pan-RAF inhibitor TAPISTRY Platform Study (NCT04589845)
Roche |
BRAF mutant/fusion tumor |
complete |
complete |
on going |
uncompleted |
none |
Roche |
|
belvarafenib(pan-RAF) pan-RAF inhibitor Monotherapy and combination
Genentech |
Solid tumors (melanoma) |
complete |
Phase 1 ongoing |
uncompleted |
uncompleted |
none |
Genentech |
|
HM43239(MKI) Myeloid kinome inhibitor such as FLT3(FMS-like tyrosine kinase 3) and SYK(Spleen tyrosine kinase)
APTOSE |
Acute myeloid leukemia |
complete |
Phase 1 ongoing |
uncompleted |
uncompleted |
none |
APTOSE |
|
Luminate® (ALG-1001) Integrin modulator
|
Retinitis pigmentosa |
complete |
Phase 1 ongoing |
uncompleted |
uncompleted |
none |
|
|
HM97662 (EZH1/2) Enhancer of zeste homolog 1/2 dual inhibitor
none |
Solid tumors, Hematologic cancers |
ongoing |
uncompleted |
uncompleted |
uncompleted |
none |
none |
|
HM99462 (SOS1) Son of sevenless homolog 1 inhibitor
none |
Solid tumors |
completed |
uncompleted |
uncompleted |
uncompleted |
none |
none |
Beijing Hanmi’s New Drug Pipeline | ||||||||
---|---|---|---|---|---|---|---|---|
BIO |
BH2950(PD-1/HER2 BsAb) A bispecific antibody for targeted immuno-oncology
INNOVENT |
Solid tumors |
completed |
On going |
uncompleted |
uncompleted |
none |
INNOVENT |
BH3120 (PD-L1/4-1BB BsAb) A bispecific antibody for targeted immuno-oncology
none |
Solid tumors |
ongoing |
uncompleted |
uncompleted |
uncompleted |
none |
none |